Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1 hi breast cancer via enhancing immune cells activity

(2018) Ri Hong et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model

(2018) Danielle Mandikian et al.   MOLECULAR CANCER THERAPEUTICS

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells

(2018) Yumei Li et al.   PLoS One

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

Bispecific antibodies: design, therapy, perspectives

(2018) Sergey Sedykh et al.   Drug Design Development and Therapy

Recent advances of bispecific antibodies in solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T-cell therapy for lung cancer and malignant pleural mesothelioma

(2017) Masha Zeltsman et al.   Translational Research

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

(2017) Simon Baldacci et al.   Oncotarget

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

(2017) Yariv Mazor et al.   Scientific Reports

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

(2017) J. Gauthier et al.   Current Research in Translational Medicine

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

(2017) Sandra L. Ross et al.   PLoS One

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro

(2016) Stefania Bellone et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

(2016) N. Haense et al.   BMC CANCER

The growing world of CAR T cell trials: a systematic review

(2016) Astrid Holzinger et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

(2016) Eugene A Zhukovsky et al.   CURRENT OPINION IN IMMUNOLOGY

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5

(2016) Yuan He et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

(2016) Joerg U Schmohl et al.   MOLECULAR THERAPY

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations

(2016) Raffaella Castoldi et al.   PROTEIN ENGINEERING DESIGN & SELECTION

TriKEs and BiKEs join CARs on the cancer immunotherapy highway

(2016) Szun Szun Tay et al.   Human Vaccines & Immunotherapeutics

microRNA Therapeutics in Cancer — An Emerging Concept

(2016) Maitri Y. Shah et al.   EBioMedicine

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

(2016) Jérôme Fayette et al.   Frontiers in Oncology

The use of combinations of monoclonal antibodies in clinical oncology

(2015) Linda M. Henricks et al.   CANCER TREATMENT REVIEWS

The Evolution of T-cell Therapies for Solid Malignancies

(2015) K. Fousek et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies and their applications

(2015) Gaowei Fan et al.   Journal of Hematology & Oncology

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms

(2015) C. M. Kurbacher et al.   ONCOLOGIST

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

(2015) Katayoun Rezvani et al.   Frontiers in Immunology

A review of blinatumomab, a novel immunotherapy

(2015) Matthew J Newman et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

(2014) Diana P. English et al.   CANCER

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a 177Lu-Labeled Peptide

(2014) Catharina M. van Rij et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies

(2014) Ignazio Caruana et al.   SEMINARS IN ONCOLOGY

Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III

(2013) D. R. Emlet et al.   CANCER RESEARCH

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

(2013) R Castoldi et al.   ONCOGENE

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma

(2013) Patrick C Gedeon et al.   Expert Review of Clinical Pharmacology

Catumaxomab

(2012) James E. Frampton   DRUGS

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)

(2012) Diane Seimetz   Journal of Cancer

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

(2011) K. Baumann et al.   GYNECOLOGIC ONCOLOGY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Catumaxomab

(2010) Rolf Linke et al.   mAbs

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

(2010) Hong Song et al.   Current Drug Delivery

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER